Sid Sijbrandij

And most people die because they, not because they've run out of treatments, they've run out of time.

Yeah, so to be clear, most of my treatments and most of my tests are happening in the US, but Europe and China are also part of it.

And what's remarkable about China, I found remarkable that I was the first, it was my first time traveling to that hospital.

Within two hours, I was checked in, they formulated

the diagnostic scan ingredients.

They gave me the scan.

They printed the results.

They talked me through it, and I was outside again.

I've not seen that speed in the US.

One other thing that's happening is that these hospitals have a lot of patients.

So instead of running a trial at 10 different hospitals, where it's a lot of work to combine all these investigators and to train all of them, you can run it in a single hospital, the same hospital where the investigator

is at, the researcher is at.

So they have a much higher speed of running trials.

And you're starting to see a giant shift in the literature of trying to do more trials and making more medicines.

Yeah, I'm doing well.

Right now we cannot detect my cancer, so that's great.

That's a really good spot to be in.

Compared to a year ago where it was growing and we had zero treatments, today I have kind of a therapeutic ladder, as in if things get worse, we'll escalate the medicine, and there's 30 medicines on it.

So we have options now.

And I'm continuing the development of 10 different drugs and diagnostics that make a lot of sense for me to have.